Comparison of the negative effect of remimazolam and propofol on cardiac contractility: Analysis of a randomised parallel‐group trial and a preclinical ex vivo study
Clinical and Experimental Pharmacology and Physiology · 2024-03 · 51 (3)
DOI: 10.1111/1440-1681.13840 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 09.01.2024. Verfasst von Yusuke Yoshikawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Propofol. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Tokyo, Japan, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Remimazolam is a newly developed ultra‐short‐acting benzodiazepine that exerts sedative effects. This study aimed to clarify the effects of remimazolam on cardiac contractility. In a randomised‐parallel group trial, haemodynamic parameters were compared between propofol ( n = 11) and remimazolam ( n = 12) groups during the induction of general anaesthesia in patients undergoing non‐cardiac surgery. In a preclinical study, the direct effects of remimazolam on cardiac contractility were also evaluated using isolated rat hearts. RNA sequence data obtained from rat and human hearts were analysed to assess the expression patterns of the cardiac γ‐aminobutyric acid type A (GABA A ) receptor subunits. In a clinical study, the proportional change of the maximum rate of arterial pressure rise was milder during the study period in the remimazolam group (propofol: −52.6 [10.2] (mean [standard deviation])% vs. remimazolam: −39.7% [10.5%], p = 0.007). In a preclinical study, remimazolam did not exert a negative effect on left ventricle developed pressure, whereas propofol did exert a negative effect after bolus administration of a high dose (propofol: −26.9% [3.5%] vs. remimazolam: −1.1 [6.9%], p < 0.001). Analysis of the RNA sequence revealed a lack of γ subunits, which are part of the major benzodiazepine binding site of the GABA A receptor, in rat and human hearts. These results indicate that remimazolam does not have a direct negative effect on cardiac contractility, which might contribute to its milder effect on cardiac contractility during the induction of general anaesthesia. The expression patterns of cardiac GABA A receptor subunits might be associated with the unique pharmacokinetics of benzodiazepines in the heart.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Anaesthesiology, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Yusuke Yoshikawa
Förderung
- Japan Society for the Promotion of Science, Tokyo, Japan
- Japan Society for the Promotion of Science
Zitieren
APA
Yoshikawa, Y., Oura, S., Kanda, M., Chaki, T., Hirata, N., Edanaga, M., & Yamakage, M. (2024). Comparison of the negative effect of remimazolam and propofol on cardiac contractility: Analysis of a randomised parallel‐group trial and a preclinical ex vivo study. Clinical and Experimental Pharmacology and Physiology, 51(3). https://doi.org/10.1111/1440-1681.13840
Vancouver
Yoshikawa Y, Oura S, Kanda M, Chaki T, Hirata N, Edanaga M, et al. Comparison of the negative effect of remimazolam and propofol on cardiac contractility: Analysis of a randomised parallel‐group trial and a preclinical ex vivo study. Clinical and Experimental Pharmacology and Physiology. 2024;51(3). doi:10.1111/1440-1681.13840
BibTeX
@article{Yoshikawa2024,
author = {Yoshikawa, Yusuke and Oura, Shunsuke and Kanda, Masatoshi and Chaki, Tomohiro and Hirata, Naoyuki and Edanaga, Mitsutaka and Yamakage, Michiaki},
title = {Comparison of the negative effect of remimazolam and propofol on cardiac contractility: Analysis of a randomised parallel‐group trial and a preclinical ex vivo study},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2024},
volume = {51},
number = {3},
doi = {10.1111/1440-1681.13840}
}
EUVIMED